JAK2 and myeloproliferative neoplasm: This is in line with our observation that a higher VAF of JAK2 mutations results more often in secondary CML, implying that a higher activity of a JAK2-mutated MPN may be a driver for secondary CML and that the CML clone depends on the JAK2-mutated clone.